Mangiferin inhibits cell migration and angiogenesis via PI3K/AKT/mTOR signaling in high glucose‑ and hypoxia‑induced RRCECs

Shi,Jia; Lv,Hongbin; Tang,Chen; Li,Yujie; Huang,Jing; Zhang,Hong

doi:10.3892/mmr.2021.12112

Mangiferin inhibits cell migration and angiogenesis via PI3K/AKT/mTOR signaling in high glucose‑ and hypoxia‑induced RRCECs

Authors:
- Jia Shi
- Hongbin Lv
- Chen Tang
- Yujie Li
- Jing Huang
- Hong Zhang
View Affiliations

Affiliations: Department of Ophthalmology, The People's Hospital of Deyang City, Deyang, Sichuan 618000, P.R. China, Department of Ophthalmology, Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan 646000, P.R. China
Published online on: April 21, 2021 https://doi.org/10.3892/mmr.2021.12112
Article Number: 473
Copyright: © Shi et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Mangiferin is a prominent active component that can be derived from several traditional herbs, including Mangifera indica L., Anemarrhena asphodeloides Bge., and Belamcanda chinensis (L.) DC., which displays antidiabetic properties. Diabetic retinopathy (DR), a serious complication caused by diabetes, is the leading cause of blindness. The present study aimed to evaluate the beneficial effects of mangiferin on high glucose (HG)/hypoxia‑induced rat retinal capillary endothelial cell (RRCEC) angiogenesis, as well as the underlying mechanisms. To establish an in vitro model of DR, RRCECs were exposed to 30 mM glucose and hypoxia. Following treatment with different doses of mangiferin (0.05, 0.1 or 0.2 µM), RRCEC viability, migration and angiogenesis were assessed by performing Cell Counting Kit 8, immunofluorescence, wound healing, Transwell and tube formation assays. Western blotting was conducted to evaluate protein expression levels. Furthermore, LY294002 and IGF‑1, an inhibitor and activator of the PI3K/AKT/mTOR signaling pathway, respectively, were used to verify the potential mechanisms underlying mangiferin. The results demonstrated that mangiferin notably inhibited HG/hypoxia‑induced RRCEC migration and angiogenesis. HG/hypoxia‑induced upregulation of hypoxia‑inducible factor‑1α, vascular endothelial growth factor, matrix metallopeptidase (MMP)2 and MMP9 expression levels and the phosphorylation of PI3K, AKT and mTOR in RRCECs was significantly reversed following treatment with mangiferin. Additionally, further activation of the PI3K/AKT signaling pathway by IGF‑1 inhibited the beneficial effects of mangiferin on RRCECs, whereas deactivation of the PI3K/AKT signaling pathway by LY294002 displayed the opposite results. Collectively, the results of the present study suggested that mangiferin suppressed RRCEC angiogenesis via modulating the PI3K/AKT/mTOR signaling pathway, which could serve as an effective treatment strategy for DR.

View Figures

View References

1	Cheung N, Mitchell P and Wong TY: Diabetic retinopathy. Lancet. 376:124–136. 2010. View Article : Google Scholar : PubMed/NCBI
2	Ting DS, Cheung GC and Wong TY: Diabetic retinopathy: global prevalence, major risk factors, screening practices and public health challenges: a review. Clin Exp Ophthalmol. 44:260–277. 2016. View Article : Google Scholar : PubMed/NCBI
3	Wang W and Lo AC: Diabetic retinopathy: Pathophysiology and treatments. Int J Mol Sci. 19:18162018. View Article : Google Scholar : PubMed/NCBI
4	Whitehead M, Wickremasinghe S, Osborne A, Van Wijngaarden P and Martin KR: Diabetic retinopathy: A complex pathophysiology requiring novel therapeutic strategies. Expert Opin Biol Ther. 18:1257–1270. 2018. View Article : Google Scholar : PubMed/NCBI
5	Kim D, Lee D, Trackman PC and Roy S: Effects of high glucose-induced lysyl oxidase propeptide on retinal endothelial cell survival: Implications for diabetic retinopathy. Am J Pathol. 189:1945–1952. 2019. View Article : Google Scholar : PubMed/NCBI
6	Mei X, Zhou L, Zhang T, Lu B, Sheng Y and Ji L: Chlorogenic acid attenuates diabetic retinopathy by reducing VEGF expression and inhibiting VEGF-mediated retinal neoangiogenesis. Vascul Pharmacol. 101:29–37. 2018. View Article : Google Scholar : PubMed/NCBI
7	Imran M, Arshad MS, Butt MS, Kwon JH, Arshad MU and Sultan MT: Mangiferin: A natural miracle bioactive compound against lifestyle related disorders. Lipids Health Dis. 16:842017. View Article : Google Scholar : PubMed/NCBI
8	Ren K, Li H, Zhou HF, Liang Y, Tong M, Chen L, Zheng XL and Zhao GJ: Mangiferin promotes macrophage cholesterol efflux and protects against atherosclerosis by augmenting the expression of ABCA1 and ABCG1. Aging (Albany NY). 11:10992–11009. 2019. View Article : Google Scholar : PubMed/NCBI
9	Núñez Selles AJ, Daglia M and Rastrelli L: The potential role of mangiferin in cancer treatment through its immunomodulatory, anti-angiogenic, apoptopic, and gene regulatory effects. Biofactors. 42:475–491. 2016. View Article : Google Scholar
10	Ding LZ, Teng X, Zhang ZB, Zheng CJ and Chen SH: Mangiferin inhibits apoptosis and oxidative stress via BMP2/Smad-1 signaling in dexamethasone-induced MC3T3-E1 cells. Int J Mol Med. 41:2517–2526. 2018.PubMed/NCBI
11	Deng Q, Tian YX and Liang J: Mangiferin inhibits cell migration and invasion through Rac1/WAVE2 signalling in breast cancer. Cytotechnology. 70:593–601. 2018. View Article : Google Scholar : PubMed/NCBI
12	Sellamuthu PS, Arulselvan P, Fakurazi S and Kandasamy M: Beneficial effects of mangiferin isolated from Salacia chinensis on biochemical and hematological parameters in rats with streptozotocin-induced diabetes. Pak J Pharm Sci. 27:161–167. 2014.PubMed/NCBI
13	Zhang Q, Kong X, Yuan H, Guan H, Li Y and Niu Y: Mangiferin improved palmitate-induced-insulin resistance by promoting free fatty acid metabolism in HepG2 and C2C12 cells via PPARα: mangiferin improved insulin resistance. J Diabetes Res. 2019:20526752019. View Article : Google Scholar : PubMed/NCBI
14	Karar J and Maity A: PI3K/AKT/mTOR pathway in angiogenesis. Front Mol Neurosci. 4:512011. View Article : Google Scholar : PubMed/NCBI
15	Huang W, Ding X, Ye H, Wang J, Shao J and Huang T: Hypoxia enhances the migration and invasion of human glioblastoma U87 cells through PI3K/Akt/mTOR/HIF-1α pathway. Neuroreport. 29:1578–1585. 2018. View Article : Google Scholar : PubMed/NCBI
16	Nyengaard JR, Ido Y, Kilo C and Williamson JR: Interactions between hyperglycemia and hypoxia: Implications for diabetic retinopathy. Diabetes. 53:2931–2938. 2004. View Article : Google Scholar : PubMed/NCBI
17	Du S, Liu H, Lei T, Xie X, Wang H, He X, Tong R and Wang Y: Mangiferin: An effective therapeutic agent against several disorders (Review). Mol Med Rep. 18:4775–4786. 2018.PubMed/NCBI
18	Saleh S, El-Maraghy N, Reda E and Barakat W: Modulation of diabetes and dyslipidemia in diabetic insulin-resistant rats by mangiferin: Role of adiponectin and TNF-α. An Acad Bras Cienc. 86:1935–1948. 2014. View Article : Google Scholar : PubMed/NCBI
19	Zhou L, Pan Y, Chonan R, Batey R, Rong X, Yamahara J, Wang J and Li Y: Mitigation of insulin resistance by mangiferin in a rat model of fructose-induced metabolic syndrome is associated with modulation of CD36 redistribution in the skeletal muscle. J Pharmacol Exp Ther. 356:74–84. 2016. View Article : Google Scholar : PubMed/NCBI
20	Miura T, Ichiki H, Hashimoto I, Iwamoto N, Kato M, Kubo M, Ishihara E, Komatsu Y, Okada M, Ishida T, et al: Antidiabetic activity of a xanthone compound, mangiferin. Phytomedicine. 8:85–87. 2001. View Article : Google Scholar : PubMed/NCBI
21	Sha H, Zeng H, Zhao J and Jin H: Mangiferin ameliorates gestational diabetes mellitus-induced placental oxidative stress, inflammation and endoplasmic reticulum stress and improves fetal outcomes in mice. Eur J Pharmacol. 859:1725222019. View Article : Google Scholar : PubMed/NCBI
22	Daud NH, Aung CS, Hewavitharana AK, Wilkinson AS, Pierson JT, Roberts-Thomson SJ, Shaw PN, Monteith GR, Gidley MJ and Parat MO: Mango extracts and the mango component mangiferin promote endothelial cell migration. J Agric Food Chem. 58:5181–5186. 2010. View Article : Google Scholar : PubMed/NCBI
23	Xiao J, Liu L, Zhong Z, Xiao C and Zhang J: Mangiferin regulates proliferation and apoptosis in glioma cells by induction of microRNA-15b and inhibition of MMP-9 expression. Oncol Rep. 33:2815–2820. 2015. View Article : Google Scholar : PubMed/NCBI
24	Li H, Huang J, Yang B, Xiang T, Yin X, Peng W, Cheng W, Wan J, Luo F, Li H, et al: Mangiferin exerts antitumor activity in breast cancer cells by regulating matrix metalloproteinases, epithelial to mesenchymal transition, and β-catenin signaling pathway. Toxicol Appl Pharmacol. 272:180–190. 2013. View Article : Google Scholar : PubMed/NCBI
25	Jia L, Sun P, Gao H, Shen J, Gao Y, Meng C, Fu S, Yao H and Zhang G: Mangiferin attenuates bleomycin-induced pulmonary fibrosis in mice through inhibiting TLR4/p65 and TGF-β1/Smad2/3 pathway. J Pharm Pharmacol. 71:1017–1028. 2019. View Article : Google Scholar : PubMed/NCBI
26	Wang N, Zhang C, Tan H, et al: Insulin accelerates progression of diabetic retinopathy through activating HIF-1α/VEGF pathway in retinal endothelial. cells. 2019.
27	Gao X, Li Y, Wang H, Li C and Ding J: Inhibition of HIF-1α decreases expression of pro-inflammatory IL-6 and TNF-α in diabetic retinopathy. Acta Ophthalmol. 95:e746–e750. 2017. View Article : Google Scholar : PubMed/NCBI
28	Zhang D, Lv FL and Wang GH: Effects of HIF-1α on diabetic retinopathy angiogenesis and VEGF expression. Eur Rev Med Pharmacol Sci. 22:5071–5076. 2018.PubMed/NCBI
29	Aiello LP, Avery RL, Arrigg PG, Keyt BA, Jampel HD, Shah ST, Pasquale LR, Thieme H, Iwamoto MA, Park JE, et al: Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med. 331:1480–1487. 1994. View Article : Google Scholar : PubMed/NCBI
30	Osaadon P, Fagan XJ, Lifshitz T and Levy J: A review of anti-VEGF agents for proliferative diabetic retinopathy. Eye (Lond). 28:510–520. 2014. View Article : Google Scholar : PubMed/NCBI
31	Cui J, Gong R, Hu S, Cai L and Chen L: Gambogic acid ameliorates diabetes-induced proliferative retinopathy through inhibition of the HIF-1α/VEGF expression via targeting PI3K/AKT pathway. Life Sci. 192:293–303. 2018. View Article : Google Scholar : PubMed/NCBI
32	Yang X, Cao J, Du Y, Gong Q, Cheng Y and Su G: Angiopoietin-like protein 4 (ANGPTL4) induces retinal pigment epithelial barrier breakdown by activating signal transducer and activator of transcription 3 (STAT3): Evidence from ARPE-19 cells under hypoxic condition and diabetic rats. Med Sci Monit. 25:6742–6754. 2019. View Article : Google Scholar : PubMed/NCBI
33	Wei J, Jiang H, Gao H and Wang G: Blocking mammalian target of rapamycin (mTOR) attenuates HIF-1α pathways engaged-vascular endothelial growth factor (VEGF) in diabetic retinopathy. Cell Physiol Biochem. 40:1570–1577. 2016. View Article : Google Scholar : PubMed/NCBI
34	Sasore T and Kennedy B: Deciphering combinations of PI3K/AKT/mTOR pathway drugs augmenting anti-angiogenic efficacy in vivo. PLoS One. 9:e1052802014. View Article : Google Scholar : PubMed/NCBI
35	Yu Z, Zhang T, Gong C, Sheng Y, Lu B, Zhou L, Ji L and Wang Z: Erianin inhibits high glucose-induced retinal angiogenesis via blocking ERK1/2-regulated HIF-1α-VEGF/VEGFR2 signaling pathway. Sci Rep. 6:343062016. View Article : Google Scholar : PubMed/NCBI
36	Zhang ZZ, Qin XH and Zhang J: MicroRNA-183 inhibition exerts suppressive effects on diabetic retinopathy by inactivating BTG1-mediated PI3K/Akt/VEGF signaling pathway. Am J Physiol Endocrinol Metab. 316:E1050–E1060. 2019. View Article : Google Scholar : PubMed/NCBI
37	Zhang Y, Wang L, Zhang Y, Wang M, Sun Q, Xia F, Wang R and Liu L: Nogo-B Promotes angiogenesis in proliferative diabetic retinopathy via VEGF/PI3K/Akt pathway in an autocrine manner. Cell Physiol Biochem. 43:1742–1754. 2017. View Article : Google Scholar : PubMed/NCBI
38	Zeng J, Zhao H and Chen B: DJ-1/PARK7 inhibits high glucose-induced oxidative stress to prevent retinal pericyte apoptosis via the PI3K/AKT/mTOR signaling pathway. Exp Eye Res. 189:1078302019. View Article : Google Scholar : PubMed/NCBI